Spartalizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Spartalizumab
Accession Number
DB14892
Type
Biotech
Groups
Investigational
Description

Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).

Synonyms
Not Available
External IDs
PDR001
Categories
Not Available
UNII
QOG25L6Z8Z
CAS number
1935694-88-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Spartalizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentRenal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Advanced Solid Tumors, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Endometrial Cancer, Anaplastic Thyroid Cancer / Anaplastic Thyroid Cancers / Chordoma and Alveolar Soft Part Sarcoma / Endometrial Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Triple Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingTreatmentMalignant Lymphomas / Tumors, Solid1
1CompletedTreatmentAdvanced Malignancies1
1CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
1Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1Not Yet RecruitingTreatmentGlioblastoma Multiforme (GBM)1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / BRAF Mutant Colorectal Cancer / Cervical Squamous Cell Cancer / Esophageal Squamous Cell Cancer / Head and Neck Carcinoma / Head and Neck Squamous Cell Cancer / Lung Squamous Cell Cancer / Malignant Neoplasm of Pancreas / Melanoma / Other Tumor Types With Documented Genetic Alterations Upstream in the Wnt Signaling Pathway / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentBone Marrow Diseases / Hematologic Diseases / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Myeloid Leukemias1
1RecruitingTreatmentBreast Cancer / Colorectal Cancers / Hepatocellular Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers1
1RecruitingTreatmentColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer / Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma / Colorectal Cancers / Non-small Cell Lung Carcinoma (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentColorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma / Colorectal Cancers / Non-small Cell Lung Cancer (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentColorectal Cancers / Esophageal SCC / Gastrointestinal Stromal Tumors / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentHER2-Negative Breast Cancer / Metastatic Epithelial Ovarian Cancer / Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Melanoma of Skin / Metastatic and Advanced Solid Tumors / Renal Cell Adenocarcinoma1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Microsatellite Stable Colorectal Cancer / Nasopharyngeal Carcinoma / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Other Solid Tumors / Ovarian Cancer1
1RecruitingTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentSolid Tumors and Lymphomas1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma1
1, 2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Solid Tumors1
1, 2Active Not RecruitingTreatmentAnaplastic Thyroid Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Other Solid Tumors / Triple Negative Breast Cancer (TNBC)1
1, 2Active Not RecruitingTreatmentCarcinoma, Pancreatic / Endometrial Carcinoma / Melanoma / Triple Negative Breast Cancer (TNBC)1
1, 2CompletedTreatmentHCC / Solid Malignancies1
1, 2Not Yet RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer AJCC v81
1, 2RecruitingTreatmentAdvanced Malignancies1
1, 2RecruitingTreatmentAdvanced Solid Tumors1
1, 2RecruitingTreatmentGastrointestinal Stromal Tumors1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of the Ovaries / Advanced Well-differentiated Neuroendocrine Tumors / Castration Resistant Prostate Adenocarcinoma / Gastric Adenocarcinoma / Lung Cancer Small Cell Lung Cancer (SCLC) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Soft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentNon-functional Neuroendocrine Tumors of Gastrointestinal Origin / Non-functional Neuroendocrine Tumors of Pancreatic Origin / Non-functional Neuroendocrine Tumors of Thoracic Origin / Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma / Well-differentiated Non-functional NET of Gastrointestinal Origin / Well-differentiated Non-functional NET of Pancreatic Origin / Well-differentiated Non-functional NET of Thoracic Origin1
2Not Yet RecruitingTreatmentHistologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment1
2Not Yet RecruitingTreatmentStage III NSCLC1
2RecruitingTreatmentDLBCL, Diffused Large B Cell Lymphoma / Head and Neck Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Melanoma / MSS, Microsatellite Stable Colon Cancer / RCC, Renal Cell Cancer / TNBC, Triple Negative Breast Cancer / Urothelial Cancer1
2RecruitingTreatmentImmunotherapy / Lung Cancer Metastatic / Malignancies1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentMalignant Neoplasm of Stomach1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
3RecruitingTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:33 / Updated on November 02, 2019 03:27